Table 2.
Islet autoantibody frequencies in T+ and T− patients with T2D
| Autoantibody | T+ (N = 133) | T− (N = 189) | All participants (N = 392) |
|---|---|---|---|
| GAD65Ab | 9 (4.8, 15.2) | 6.3 (3.3, 10.8) | 7.8 (5.4, 10.9) |
| IA2Ab | 4.5 (1.7, 9.6) | 7.4 (4.1, 12.1) | 6 (3.9, 8.9) |
| ZnT8Ab | 2.3 (0.5, 6.4) | 0.5 (0, 2.9) | 1.5 (0.6, 3.3) |
| One autoantibody | 12.8 (7.6, 19.7) | 12.2 (7.9, 17.7) | 13.5 (10.3, 17.3) |
| Two autoantibodies | 1.5 (0.2, 5.3) | 2.1 (0.6, 5.3) | 1.5 (0.6, 3.3) |
| Three autoantibodies | 1.5 (0.2, 5.3) | 0 (0, 1.9) | 0.5 (0.1, 1.8) |
Data are % (95% CI). T-cell assays (cellular immunoblotting tests) were not completed in 70 of 392 participants who had serum autoantibody tests.
T+ is reactivity to ≥4 blots; T− is reactivity to ≤3 blots.